Advanced searches left 3/3

ACE Inhibitor - Springer Nature

Summarized by Plex Scholar
Last Updated: 10 April 2022

* If you want to update the article please login/register

Beta-blocker/ACE inhibitor therapy differentially impacts the steady state signaling landscape of failing and non-failing hearts

Heart failure is a multifactorial disease that affects an estimated 38 million patients around the world. Combination therapy with angiotensin-converting enzyme inhibitors and -adrenergic receptor blockers is also used as a treatment for non-cardiac disorders in heart failure with reduced ejection fraction. Our knowledge of the cellular changes accompanying chemotherapy with ACEi and -AR blockers is limited. In cardiac left ventricles, we used proteomics and phosphorylation methods to determine the global changes in protein content and phosphorylation state in cardiac left ventricles as a result of combination therapy of -AR blocker and ACE inhibitor in HFrEF and control hearts.

Source link: https://doi.org/10.1038/s41598-022-08534-0

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions